Axitinib (off Label)
Axitinib + avelumab Phase 2 (MD Anderson)
Pfizer · Phase 2 · Completed · Enrollment 40
| Arm | Reported safety |
|---|---|
| Axitinib + avelumab | serious treatment-related adverse events: 29%, primary analysis |
| Axitinib + avelumab, ACC-I subtype | n/r |
| Axitinib + avelumab, ACC-II subtype | n/r |
A count stays a count. This page does not turn a count into a percent.